CLEC3A

Across TCGA pan-cancer cohorts, CLEC3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLEC3A data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLEC3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC3A expression acts as an unfavorable survival marker.

LUAD, GBM, and SKCM are the cancer types where CLEC3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.237	0.788	.008	9	view →
GBM	OS	Median	All	0.101	0.413	.035	3	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLEC3A–LUAD (OS)

Open the LUAD breakdown →